Pharmacokinetic and Safety Study of Pixantrone in Patients With Metastatic Cancer and Hepatic Impairment (Hepatic)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01632436
Recruitment Status : Unknown
Verified June 2012 by CTI BioPharma. Recruitment status was: Active, not recruiting
This study will be conducted in patients with metastatic cancer and either moderate, severe, or no hepatic impairment who have failed other antineoplastic therapies or for whom there is no standard therapy. The study will be conducted in two stages. Using an existing pixantrone population pharmacokinetic (PPK) model, a model-based strategy will be used to evaluate the findings from the first stage of the study conducted in patients with moderate hepatic impairment and matched controls. The PPK evaluation will be completed prior to enrolling patients with severe hepatic impairment and additional matched controls during the second stage of the study. Patients with hepatic impairment will be paired with matched control patients with normal hepatic function, matched on gender, age, and body surface area (BSA).
Condition or disease
This study will be conducted in patients with metastatic cancer and either moderate, severe or no hepatic impairment who have failed other antineoplastic therapies or for whom there is no standard therapy. The study will be conducted in two stages. Stage I will include patients with moderate hepatic impairment and Stage II will include patients with severe hepatic impairment. An analysis of data from the Stage I portion of the study will be performed to decide whether to enroll patients in the Stage II portion of the study. Patients with hepatic impairment (either moderate or severe) will be paired with matched control patients with normal hepatic function, matched on gender, age, and body surface are (BSA). Patients will receive a single dose of pixantrone on day 1 of a 21 day cycle. Blood samples will be obtained at various time points during the first week of the first cycle for pharmacokinetic (PK) analysis. If any patient with hepatic impairment develops a dose limiting toxicity, subsequent patients will be administered a lower dose of pixantrone. If any patient with hepatic impairment who is receiving the reduced dose of pixantrone experiences a dose limiting toxicity, the study will be terminated. Patients who demonstrate any clinical, radiologic, or other evidence of response or stabilization after the initial dose of pixantrone and who wish to continue treatment may do so at the discretion of the Investigator. Patients receiving additional cycles will be treated with pixantrone every 21 days for up to 5 additional cycles and will be followed for safety only, until 30 days after the last dose.
A Non-randomized Cohort Study With Matched Controls Investigating Pharmacokinetic Parameters and Safety of a Single Dose of Pixantrone With Metastatic Cancer and Moderate, Severe, or No Hepatic Impairment.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Signed Institutional Review Board (IRB) approved consent form
Age ≥ 18 years old
Histological confirmation of cancer from any previous cytological or tissue report
Diagnosis of metastatic disease based on biopsy, imaging, or clinical criteria
Failure of other antineoplastic therapies, or disease for which no standard therapy exists
At least 28 days since last antineoplastic therapy
ECOG PS ≤ 2 (see Appendix 8.2)
Life expectancy ≥ 12 weeks in Investigator's judgment
LVEF ≥ 50% by echocardiogram
Hemoglobin ≥ 8 g/dL (can be post transfusion)
Platelets ≥ 75 x 109/L
ANC > 1.5x109/L
Stage I, moderate hepatic impairment: 1.5 < total serum bilirubin ≤ 3.0 ULN Stage II, severe hepatic impairment: 3.0 < total serum bilirubin < 4.0 ULN Stages I and II, normal liver function: total bilirubin < 1.0 ULN
Serum creatinine ≤ 1.0 x ULN
All acute toxicities related to prior treatment recovered to grade ≤ 1 or baseline except alopecia
Willingness and ability to comply with the visit schedule and assessments required by the study protocol
If fertile, both males and females must agree to use appropriate and effective contraception (oral contraceptives, barrier methods, approved contraceptive implant, long-term injectable contraception, or intrauterine device) for the duration of study participation and for 6 months after last dose of study drug.
Prior treatment with a cumulative dose of doxorubicin or equivalent exceeding 450 mg/m² according to the calculation index in Appendix 8.1
Total serum bilirubin > 4.0 ULN
LVEF < 50% by echocardiogram
Active grade 3/4 infection
Major surgery ≤ 28 days prior to first dose
Known human immunodeficiency virus
Any antineoplastic therapy ≤ 28 days prior to first dose
New York Heart Association Classification III or IV heart disease (see Appendix 8.3)
Any contraindication or known allergy or hypersensitivity to the study drug
Pregnant or lactating
Concomitant therapy with anticancer agents (corticosteroid use is permitted)
Any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study procedures or follow-up schedule
Severe and/or uncontrolled medical disease that could compromise participation in the study or any medical or psychiatric condition that in the opinion of the Investigator would make study drug administration hazardous or obscure the interpretation of data